CLX - Educational Analysis * US Equities
Educational Analysis * US Equities

CLX

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerCLX
CategoryEducational primer
Last reviewedNovember 9, 2026
You're viewing an older edition of this page.Read the latest edition →

Business Profile & Competitive Position

The Clorox Company (CLX) sits in the Consumer Defensive sector under the Household & Personal Products industry. It is a multinational manufacturer and marketer with fiscal 2026 net sales of roughly $6.7 billion, about 9,200 employees, operations in approximately 25 countries and sales in about 95 markets. The consumer brand portfolio includes Clorox bleach, Pine-Sol, Glad, Fresh Step, Kingsford charcoal, Hidden Valley, Brita and Burt’s Bees; professional sales run under Purell, CloroxPro and CloroxHealthcare. In April 2026 the company closed the GOJO Industries acquisition, expanding its health-and-hygiene footprint and strengthening its business-to-business presence.

Those household names imply some brand-driven pricing power, but the numbers add texture. The 9.4% net margin is healthy for a staples manufacturer yet not deep enough on its own to indicate a wide economic moat; it simply says Clorox can price slightly above commodity levels for familiar cleaning, pet-care and food-related products. The more striking figure is ROE of -1920.6%. A negative ROE of that magnitude is usually a balance-sheet artifact—negative or very thin shareholders’ equity—rather than an operating-loss signal. Consequently, ROE here is not a useful measure of brand economics; the real competitive question is whether that margin can hold while Clorox manages whatever leverage, buybacks or accounting items produced the equity distortion.

Financial Posture

Clorox currently carries a $12.1 billion market cap and trades at a P/E of 18.0. The 0.58 beta fits the low-volatility, defensive profile typical of household-products names. Net margin of 9.4% describes a business that converts sales into profit reasonably well, but with limited cushion if resin, freight or labor costs spike.

The headline -1920.6% ROE again dominates the posture discussion. Because equity is negative or negligible, the standard “profit per dollar of shareholder equity” interpretation collapses. Investors evaluating CLX should therefore look past that metric to leverage ratios, free-cash-flow coverage, pension obligations and dividend sustainability. At the current price of $99.96, the stock sits above its 50-day EMA of $89.99 and the RSI is 74.0, both of which describe short-term momentum rather than long-term value. All together, CLX’s valuation is middle-of-the-road for a large-cap defensive consumer name, while its balance-sheet signals require closer inspection than a simple P/E screen would provide.

Strategic Priorities & Outlook

Clorox’s most recent 10-K frames strategy under the IGNITE framework built on four choices: fuel long-term profitable growth, innovate consumer experiences, reimagine how the company and its people work, and continuously evolve the product portfolio. Operationally, management is focused on completing and optimizing a new enterprise resource planning (ERP) system and a broader digital transformation, with the goal of generating long-term efficiencies across supply chain, digital commerce, innovation and brand building.

Near-term priorities also include investing in strong brands and strategic digital capabilities while streamlining the operating model. Health and hygiene expansion is a major theme, especially integrating GOJO and growing professional and institutional markets. The filing also flags challenges: fiscal 2026 saw declines in organic sales and earnings, with diluted EPS down 26%, partly reflecting macroeconomic headwinds and ERP-transition timing that had pulled some sales into fiscal 2025. Customer concentration is material: Walmart accounted for 26% of consolidated FY2026 net sales, while the five largest customers represented about half of net sales. Separately, the Glad bags and wraps venture with P&G expired on January 31, 2026, requiring Clorox to purchase P&G’s 20% interest; Glad retained core intellectual-property licenses on a royalty-free basis.

Macro & Geopolitical Exposure

As a Household & Personal Products company, CLX is exposed to the regulatory and supply-chain environment typical of the sector. Cleaning chemicals, food-contact items, personal-care formulations and health/hygiene products face oversight from the EPA, FDA and FTC, plus state-level rules around ingredients, labeling and packaging. Changes in those regulations can raise compliance costs or force reformulations.

Trade policy matters because resins, packaging materials and other inputs are sourced globally; tariffs or logistics disruptions can squeeze a 9.4% net margin. With sales in roughly 95 markets, currency translation can also move reported results. Demand is generally defensive—household cleaning, charcoal, trash bags and personal care hold up better than discretionary categories in downturns—but volume can still soften if consumers trade down to private-label alternatives. Retail concentration magnifies that risk: Walmart alone represented one-quarter of FY2026 sales, so a small change in shelf space, inventory posture or pricing terms at a handful of major retailers can carry outsized consequences.

Recent Developments

Recent news has treated CLX largely as a dividend and relative-value idea. On November 9, 2026, Benzinga noted Clorox appearing alongside Take-Two, ExxonMobil and a financial stock in CNBC’s “Final Trades” segment. On November 6, 2026, Defenseworld.net published a side-by-side look at Clorox versus Reynolds Consumer Products (REYN). On November 5, 2026, The Motley Fool included Clorox among “3 High-Yielding Dividend Stocks That Investors Can Safely Buy and Hold for Decades,” and on November 4, 2026, the same outlet contrasted Clorox with PepsiCo in a dividend-stock comparison. None of these items carry new fundamental data, but the clustering of dividend-focused coverage in early November 2026 fits the stock’s low-beta, income-oriented profile and explains why investor attention tends to center on payout sustainability rather than growth momentum.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, CLX has beaten consensus earnings expectations 6 out of 8 times (75%), with an average surprise of 11.1%. The average five-day price move in the trading sessions after those reports is +3.58%, classified as an upward drift, so the stock has historically continued to absorb positive surprises beyond the initial headline reaction.

The four most recent reports show how noisy that pattern can be. On November 2, 2026, CLX reported EPS of $1.55 versus a $1.07 estimate—a 44.9% positive surprise—yet the stock rose only 4.34% the next day and was flat over the next five sessions. On August 3, 2026, a 1.2% beat ($1.66 vs. $1.64) produced a 6.52% next-day gain and a 9.61% five-day drift. By contrast, on April 30, 2026, EPS of $1.64 beat the $1.55 estimate by 5.8%, but the stock fell 9.67% the next day and drifted -4.49% over the following five sessions. On February 3, 2026, CLX missed by 2.8% ($1.39 vs. $1.43) yet still rose 2.43% the next day and drifted 5.63% higher over the next week.

The next scheduled report is February 2, 2027 after the close, with the consensus EPS estimate at $1.07. At the current price of $99.96 and an RSI of 74.0, the market has already moved, but the historical 75% beat rate, 11.1% average surprise and +3.58% average post-earnings drift provide context for how the release might be interpreted relative to the market’s real expectation.

Frequently Asked Questions

Why is Clorox’s ROE reported as negative?

ROE of -1920.6% is extreme and is usually a balance-sheet artifact, such as negative or very thin shareholders’ equity, rather than a measure of operating losses. For CLX, ROE is not a reliable competitive-moat metric and should be supplemented with leverage, cash-flow and debt-coverage analysis.

What are Clorox’s main strategic priorities?

The 10-K outlines the IGNITE strategy built on profitable growth, consumer experience innovation, reimagining work and evolving the portfolio. Near-term execution focuses on ERP/digital transformation, brand investment, cost streamlining, and integrating the GOJO acquisition to expand health and hygiene in professional markets.

How has CLX typically behaved after earnings?

Over the last eight quarters CLX has beaten estimates 75% of the time, with an average surprise of 11.1% and an average five-day post-earnings drift of +3.58%. Individual quarters vary widely, however, including a 9.67% one-day drop after an April 2026 beat and a positive five-day drift after a February 2026 miss.

For a deeper dive into how sell-side and institutional models currently view Clorox—including balance-sheet risks, dividend coverage, margin assumptions and post-earnings positioning—review the full institutional verdict on the ticker page.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 9, 2026
The Clorox Company · Consumer Defensive / Household & Personal Products
$12.1BMarket cap
18.0P/E
9.4%Net margin
-1920.6%ROE
75%Beat rate, last 8Q
11.1%Avg EPS surprise
3.58%Avg 5-day move after earnings
2027-02-02Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-11-02$1.55$1.07+44.9%+4.34%null%
2026-08-03$1.66$1.64+1.2%+6.52%+9.61%
2026-04-30$1.64$1.55+5.8%-9.67%-4.49%
2026-02-03$1.39$1.43-2.8%+2.43%+5.63%
2025-11-03$0.85$0.818+3.9%--
2025-07-31$2.87$2.2+30.5%--

Previous CLX editions

Beyond the primer

Get the institutional verdict on CLX

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the CLX verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.